When you see a semaglutide study summarized in a few numbers, the support participants received can disappear from the story. STEP 3 is worth a closer look because both groups received a substantial, structured behavioral program throughout the trial.
The study compared weekly injectable semaglutide with placebo over 68 weeks. It did not test whether everyone needs the same counseling schedule or meal plan. Here's how to read what it did test.
Who was in the study?
STEP 3 enrolled 611 adults with overweight or obesity who did not have diabetes. Participants were randomly assigned to receive either semaglutide or a placebo injection. Neither participants nor the study team knew which injection a person received during the blinded part of the trial.
The semaglutide group included 407 people and the placebo group 204. The target semaglutide dose in this study was 2.4 mg once weekly, reached through a dose-escalation schedule. That is a description of the research, not an instruction for starting or changing a prescription.
The study was funded by Novo Nordisk, the manufacturer of semaglutide. Funding is relevant context when evaluating research alongside its methods, results, and limitations.
What did “behavioral support” mean here?
Both groups were offered 30 individual counseling visits with a registered dietitian across the 68 weeks. The program addressed food, physical activity, and strategies for making and maintaining changes. Participants also used a structured, low-calorie meal-replacement plan during the first eight weeks, followed by a plan using conventional foods.
That's a specific research program, not a universal prescription. Thirty visits may be difficult to access or pay for outside a trial. A structured meal replacement may not suit someone's health history, preferences, budget, or relationship with food. Don't copy the trial's diet without discussing your needs with a qualified professional.
The details matter because the placebo group was not left without support. Both groups received the program, while the randomized difference was the study injection. That helps clarify what the comparison can tell us.
What were the results?
At week 68, the estimated average change from starting body weight was a loss of 16.0% in the semaglutide group and 5.7% in the placebo group. The estimated difference was 10.3 percentage points. Those averages describe groups in this trial, not a guaranteed outcome for an individual.
Participants' experiences varied. An average doesn't show every person's result, whether they stayed on the assigned treatment for the entire study, or how their weight might change after the study ends. The researchers used a planned analysis intended to account for what happened across the trial, including treatment discontinuation.
The study also looked at other outcomes and side effects. Weight change was the main result, but the overall decision about care involves more than a single number.
Side effects were part of the picture
Digestive adverse events were reported by 82.8% of participants in the semaglutide group and 63.2% in the placebo group during the trial. These categories included symptoms such as nausea, constipation, diarrhea, and vomiting. Reporting an event at some point during 68 weeks doesn't mean everyone had the same symptom, severity, or duration.
Serious adverse events were reported in 9.1% of the semaglutide group and 2.9% of the placebo group. An event recorded during a trial is not automatically proven to be caused by the treatment, but it belongs in a balanced reading of the results. Some participants stopped treatment because of adverse events.
If you're using a medication and symptoms make it hard to eat, drink, or go about your day, contact your prescriber. If you cannot keep fluids down, seek urgent medical care. Seek urgent care for severe symptoms or when your care team advises it.
What STEP 3 can't answer
Because both groups received the same intensive program, STEP 3 cannot tell us whether 30 visits are better than fewer visits, whether meal replacements are necessary, or which part of the counseling program mattered most. Those would require different comparisons.
It also cannot establish how every person with diabetes, a different health history, or a different support system would respond. The participants met the study's entry criteria and received care in a particular research setting. Your routine and access to support may look different.
Comparing the headline result with another trial can be tempting, but studies often differ in participants, support, and methods. A difference between two study averages doesn't by itself prove that one counseling plan caused the difference.
Bringing the study into a real appointment
You might ask: “What kind of nutrition or behavioral support would be useful for me, and what is available?” Support could involve a dietitian, a group program, practical meal planning, help with activity, or another approach you and your team choose. The best fit depends on your needs and resources.
You can also ask how to monitor side effects, what goals to track beyond weight, and when to review the plan. If a program feels too restrictive or isn't accessible, say so. Treatment should work in your life, not only in a study protocol.
STEP 3 showed a difference between semaglutide and placebo when both were paired with the same structured support. Its value is in that specific comparison—and in the reminder to look at the care surrounding the injection, not just the headline number.










